TNFRSF8 and classic Hodgkin lymphoma: One of the most extensively studied bispecific antibodies in cHL is AFM13, which targets CD30, highly expressed on HRS cells, and CD16A on natural killer (NK) cells, facilitating antibody-dependent cellular cytotoxicity (ADCC).